Yu-Ching Lee

Correction: Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients

Tzu‐Chun Cheng, Mien‐Chie Hung, Lu-Hai Wang, Shih‐Hsin Tu et autres

tw, us (code pays fourni par la source)

Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients

Tzu‐Chun Cheng, Mien‐Chie Hung, Lu-Hai Wang, Shih‐Hsin Tu et autres

BACKGROUND: Up to 23% of breast cancer patients recurred within a decade after trastuzumab treatment. Conversely, one trial found that patients with low HER2 expression and metastatic breast cancer had a positive response to trastuzumab-deruxtecan (T-Dxd). This indicates that relying solely on …

tw, us (code pays fourni par la source)

Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies

Keng‐Chang Tsai, Yu-Ching Lee, Tien-Sheng Tseng

The rapid spread of SARS-CoV-2 has caused the COVID-19 pandemic, resulting in the collapse of medical care systems and economic depression worldwide. To combat COVID-19, neutralizing antibodies have been investigated and developed. However, the evolutions (mutations) of the receptor-binding domain (RBD) of …

tw (code pays fourni par la source)

Correction to: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Grace Wakabayashi, Yu-Ching Lee, Frank Luh, Chun-Nan Kuo et autres

In the original publication of this article [1] the name of the fifth author is uncorrect. The correct name of the fifth author should be Wei-Chiao Chang rather than Wei-Chao Chang. The original publication has been corrected.

tw (code pays fourni par la source)